CSPC Pharmaceutical 9M profit jumps on Astrazeneca licence fee boost

By Reuters News


Overview

  • China pharmaceutical group's nine-month revenue rose 27% yr/yr, driven by finished drugs and licence fees

  • Net profit attributable to shareholders more than doubled, up 101.5% yr/yr

  • Bulk products and functional food revenues declined due to lower prices and competition


Outlook

  • CSPC Pharmaceutical is eligible for up to $3.5 bln development and $13.8 bln sales milestones from AstraZeneca


Result Drivers

  • ASTRAZENECA LICENCE INCOME – RMB5.74 bln of the upfront payment was recognised as licence fee income, contributing significant Group revenue

  • FINISHED DRUGS GROWTH - Finished drugs revenue rose 40.1%, driven by higher sales in nervous system and digestion/metabolism therapeutic areas and increased licence fees

  • VITAMIN C PRICING – Vitamin C revenue fell 18.9% to RMB1,451 mln, which the Co said was primarily due to lower selling prices

  • ANTIBIOTICS COMPETITION – Antibiotics revenue fell 27.3% to RMB885 mln, which the Co said was mainly due to intensified competition and volume-based procurement


Company press release: Full Story


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

9M Revenue

RMB 25.26 bln

9M Net Income Attributable

RMB 7.08 bln


Analyst Coverage

  • The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 16 "strong buy" or "buy", 3 "hold" and 2 "sell" or "strong sell"

  • The average consensus recommendation for the pharmaceuticals peer group is "buy"

  • Wall Street's median 12-month price target for CSPC PHARMACEUTICAL GROUP LIMITED is HK$12.00, about 52.1% above its November 17 closing price of HK$7.89

  • The stock recently traded at 14 times the next 12-month earnings vs. a P/E of 14 three months ago


Reuters Recommended Reads

  • Nov 16 - AstraZeneca fends off lawsuit over alleged Soliris drug monopoly

  • Nov 16 - ALX Oncology Q3 net loss per share narrows

  • Nov 16 - Larimar Therapeutics Q3 net loss narrows as R&D expenses fall


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.